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Abstract
Tumor progression is promoted by Tumor-Associated Macrophages (TAMs) and metastasis-induced bone destruction by
osteoclasts. Both myeloid cell types depend on the CD115-CSF-1 pathway for their differentiation and function. We used 3
different mouse cancer models to study the effects of targeting cancer host myeloid cells with a monoclonal antibody
(mAb) capable of blocking CSF-1 binding to murine CD115. In mice bearing sub-cutaneous EL4 tumors, which are CD115-
negative, the anti-CD115 mAb depleted F4/80+ CD163+ M2-type TAMs and reduced tumor growth, resulting in prolonged
survival. In the MMTV-PyMT mouse model, the spontaneous appearance of palpable mammary tumors was delayed when
the anti-CD115 mAb was administered before malignant transition and tumors became palpable only after termination of
the immunotherapy. When administered to mice already bearing established PyMT tumors, anti-CD115 treatment
prolonged their survival and potentiated the effect of chemotherapy with Paclitaxel. As shown by immunohistochemistry,
this therapeutic effect correlated with the depletion of F4/80+CD163+ M2-polarized TAMs. In a breast cancer model of bone
metastasis, the anti-CD115 mAb potently blocked the differentiation of osteoclasts and their bone destruction activity. This
resulted in the inhibition of cancer-induced weight loss. CD115 thus represents a promising target for cancer
immunotherapy, since a specific blocking antibody may not only inhibit the growth of a primary tumor through TAM
depletion, but also metastasis-induced bone destruction through osteoclast inhibition.
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Introduction
Macrophages and osteoclasts are myeloid cell types known to
contribute to cancer progression at various stages of the disease [1–
5]. Their differentiation and function are regulated by CD115 (M-
CSFR, CSF-1R, c-fms), encoded by the c-fms proto-oncogene and
belonging to the class III receptor tyrosine kinase family [6].
CD115 is the sole cell-surface receptor identified to date for
colony-stimulating factor-1 (CSF-1), a major cytokine regulating
the differentiation, proliferation and migration of myeloid lineage
cells [7]. Interleukin-34 (IL-34) has more recently been identified
as another CD115 ligand with comparable biological effects [8].
While the regulation and function of IL-34 during cancer
progression remain to be investigated, experimental and clinical
evidence have largely documented the central role of CSF-1 in
tumor development and metastasis.
In humans, CD115 and CSF-1 overexpression are frequent in a
wide variety of epithelial tumors (breast, prostate, endometrial,
cervical, ovarian cancers) and have been correlated with more
aggressive diseases and poor prognosis [9–13]. In breast tumors,
CD115 was found to be expressed both by tumor cells and by
infiltrating macrophages [14]. It was suggested by S. Scholl et al.
[15] that CSF-1 might not only act as an autocrine growth factor
for tumor cells, but also recruit macrophages to the tumor site
promoting tumor progression. In the MMTV-PyMT (PyMT)
mouse model of spontaneous breast cancer, CSF-1 produced by
tumor cells was indeed shown to be an important chemoattractant
for macrophages and to enhance their infiltration into the primary
tumor [16]. Tumor-associated macrophages (TAMs) regulate the
angiogenic switch through induction of angiogenic factors such as
vascular endothelial growth factor and produce matrix-metallo-
proteases, which can regulate angiogenesis and facilitate metastasis
[17,18]. Metastatic cells require CD115-positive macrophages for
extravasation and growth into their metastatic site [5]. In vivo
invasion assays have shown that TAMs co-migrate with breast
tumor cells and contribute to tumor cell invasion through a
paracrine loop involving epidermal growth factor, produced by
macrophages, and CSF-1 produced by cancer cells [19–21]. In
addition, CSF-1 has been shown to polarize macrophages towards
an alternatively-activated, trophic or M2-type, endowed with
immunosuppressive activity and characterized notably by CD163
expression [22–28]. High numbers of TAMs, which can constitute
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the most abundant immunosuppressive cell population in the
tumor microenvironment, have been correlated with bad progno-
sis in many cancers including breast [1,2,4,23]. Because of their
pleiotropic roles in tumor progression, TAMs represent an
important target for cancer therapy [29].
CSF-1 overexpression by bone metastases may also contribute
to the differentiation of osteoclasts, leading to bone lesions and
pain in cancer patients. Osteoclasts, like macrophages, are
dependent on the CD115/CSF-1 pathway for their differentiation
[30]. CSF-1 notably induces RANK expression by osteoclast
precursors [31–33]. Recent results indicate that CSF-1 is a potent
stimulator of mature osteoclast bone-resorbing activity, in addition
to RANK/RANKL [32]. Both cell-surface and secreted CSF-1
produced by tumor cells metastatic to bone can contribute to
induce osteoclast formation [3].
We have studied the effects of targeting CD115 in 3 different
mouse cancer models characterized by the infiltration of M2-
polarized TAMs in the primary tumors or by the formation of
osteolytic bone metastases. To this purpose, we used a monoclonal
antibody (mAb), AFS98, known to block CSF-1 binding to murine
CD115-expressing cells and to inhibit CSF-1-dependent colony
formation by mouse bone marrow precursors [34]. This mAb has
been used by other authors to deplete myeloid cell subsets in
various experimental mouse models [19,29,35,36].
Our results highlight the potential of cancer immunotherapy
with an anti-CD115 mAb, which can inhibit tumor growth by
depleting TAMs, synergize with chemotherapy and prevent bone
destruction by osteoclasts.
Materials and Methods
Antibodies
The hybridoma AFS98 secreting rat anti-mouse CD115 IgG2a
was kindly provided by Pr S. Nishikawa (RIKEN Center for
Developmental Biology, Japan). The mAb was produced by
culture of the hybridoma in complete RPMI medium containing
5% FCS and purified on protein G (Millipore) and diafiltration on
Pellicon 3 30 kDA (Millipore). Rat IgG used as negative control
was from Rockland/Tebu-bio. In some instances, mAb AFS98
and isotype control rat IgG2a were purchased from eBiosciences.
Cell Lines
The EL4 murine lymphoma cell line (ATCC TIB-39) was
cultured in complete DMEM medium (Sigma-Aldrich) with 10%
FCS (PAA Laboratories) with 40 mg/mL gentamycin (Schering-
Plough) and 2 mM glutamine (Sigma). MDA-MB231SA-GFP6
human breast cancer cells used in the metastasis-induced osteolysis
model were obtained by Pharmatest (Turku, Finland) from Dr
Theresa Guise (Indiana University, Indianapolis, USA) [37,38]
and transfected with pTurboGFP-N vector (Evrogen).
Immunofluorescence
Mouse formalin-fixed paraffin-embedded tissue sections were
deparaffinized and rehydrated, and epitopes were retrieved by
boiling in a 10 mM Citrate Buffer pH 6. EL-4 cryosections were
rehydrated and fixed in acetone. Sections were saturated with 3%
H2O2 and 10% goat serum to eliminate endogenous peroxidase
activity and non-specific staining, respectively, before incubation
for 90 min at room temperature with antibodies against F4/80
(BM8, ref. MF48000, Caltag) or CD163 (M-96, ref. sc-33560,
Santa Cruz). Envision system (HRP-conjugated polymer coupled
to secondary antibodies, ref. K4003, Dako) and TSA-Cy3 (ref.
SAT704A, Perkin Elmer) was used for signal amplification. Finally
sections were counterstained with 0.5 mg/mL DAPI (Hoechst
33258, B-2883, Sigma) and mounted in MowiolH (Calbiochem).
Isotype-matched control antibodies were used as negative controls.
Images were acquired with an optical microscope 90i (Nikon)
equipped with 40x objective and epifluorescence (scale
bar = 50 mm). Signal was quantified on section scans (Nanozoo-
mer, Hamamatsu) using the ImageJ (http://rsb.info.nih.gov/ij)
free software. To this aim, images were split into 3 channels (red,
green and blue). The blue channel allows quantifying the blue
pixels defining the tumor section surface, while the red channel
measures the red pixels corresponding to the immunostained
surface. The percentages of positive cells are calculated as (red
pixels/blue pixels) x100.
Preclinical Mouse Models
Experiments performed in the EL-4 and PyMT cancer models
were performed in full compliance with the CEE directive 2010/
63 of September 22d, 2010 relating to the protection of animals
used for experimental or other scientific purposes and in
compliance with the French law (de´cret nu 2013–118 of February
1st, 2013) and approved by the Comite´ National de Re´flexion
Ethique sur l’Experimentation Animale (CNREEA, Ethical
Committee TG number 93). The experiments in the breast
cancer bone metastasis model were approved by the Finnish
National Committee for Animal Experiments (license number
STH667A).
EL4 Tumor Model
Five-week old C57BL/6 mice (Charles River Laboratories)
were housed in a specific-pathogen free animal facility and
acclimated for one week before the experiments. At day 0, 104 EL-
4 cells were injected subcutaneously into the right flanks of mice.
Ten days after tumor implantation, mAbs diluted in PBS were
dosed IP at 10, 25 or 50 mg/kg to groups of 21 mice. Injections
were performed 3 times per week for 3 weeks. Tumor volumes
were monitored twice a week by caliper measurements of each
dimension and calculated using the following formula: V= 4/3 p
(length/2)(width/2)(depth/2). Three mice per group bearing EL4
tumors were sacrificed at days 20 and 27, when tumors were
sampled for macrophages detection by immunofluorescence. Mice
were euthanized by cervical dislocation when tumor volumes
reached 3000 mm3 or when animals showed distress, to avoid
unnecessary suffering. Statistics on tumor volumes (n = 15 mice/
group) were performed using the Kruskal-Wallis test followed by
Mann-Whitney’s test for pairwise comparisons. Log-rank test was
used for the statistical analysis of mouse survival (n = 15).
PyMT Tumor Model
MMTV-PyMT (PyMT) transgenic mice were obtained from the
Mayo Foundation for Medical Education and Research (Roche-
ster, Minnesota) and housed in a specific-pathogen free animal
facility. The strain was maintained by backcrossing on the
C57BL/6 background. When PyMT mice reached 10 weeks of
age (early treatment), 10 mice per group were administered with
mAbs through the IP route, 3 times per week for 4 weeks for
studying tumor growth and mouse survival. Late treatment was
performed similarly but starting from week 16. MAbs were given
at the dose of 50 mg/kg, diluted in PBS. Tumor volumes were
monitored every 7 days by caliper measurements of 3 dimensions
and calculated using the following formula: V=4/3 p (length/
2)(width/2)(depth/2). To avoid unnecessary suffering, mice were
euthanized by cervical dislocation when total tumor volumes, i.e.
the sum of all measurable tumors, were above 2000 mm3. Statistics
on tumor volumes were performed using the Kruskal-Wallis test
followed by Mann-Whitney’s test for pairwise comparisons.
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Statistics on survival were performed using the Log-rank test. In
repeat experiments performed on 3 mice per group, the animals
were sacrificed by cervical dislocation one week after the
termination of the treatment. Three to 5 tumors per mice were
sampled for immunofluorescence and histopathology.
Histopathology
The progression of primary tumors was analyzed on tumor
sections from 4 to 25 week-old PyMT mice. Briefly, mammary
glands were fixed in 10% formalin at 4uC and then dehydrated.
Tissues were paraffin-embedded, sectioned, and stained with
hematoxylin and eosin (H&E). Tumor staging was performed
based on the four-stage classification previously described for
PyMT mice [39].
MDA-MB231 Breast Cancer Metastasis-induced Osteolysis
Model
Five-week old female athymic nude mice (Harlan) anesthetized
with Xylazin (4–5 mg/ml) and Ketamine (75–92 mg/ml) were
inoculated with MDA-MB231SA-GFP6 cells (105 cells in 0.1 ml of
PBS) by the intracardiac route. Allocation to groups of 15 mice
was performed by randomization procedure based on body
weight. Treatment was started on the day of intracardiac
inoculation, at day 0. Fifty mg/kg of mAb AFS98 or control rat
IgG (Rockland, Tebu-bio) were administered IP 3 times per week,
while zoledronic acid (Zometa, Novartis) was injected SC at
0.1 mg/kg on days 0 and 14. Analgesia (buprenorphine 0.1 mg/
kg, SC twice a day) was used for the last 5 days of the study. Blood
samples for analyzing tartrate-resistant acid phosphatase isoform
5b (TRACP 5b) were collected before the beginning of admin-
istration and at days 17 and 24. Serum TRACP 5b was analyzed
using MouseTRAPTM ELISA kit (IDS Ltd). Statistical analysis of
the results was performed using one-way ANOVA after logarith-
mic transformation of the data, followed by Dunnett’s test for
pairwise comparisons. Osteolysis was measured by radiographic
analysis of the animals under anesthesia prior to sacrifice, using the
Faxitron Specimen Radiographic System MX-20 D12 (Faxitron
Corp.) and Faxitron Dicom 3.0–software. At least two radiographs
(both hind limbs and thorax) per animal were taken each time.
The lesion number and area in hind limbs was determined from
the images with MetaMorph image analysis software. Statistical
analysis was performed using Kruskal-Wallis test followed by
Mann-Whitney’s test for pairwise comparisons. Mice were
sacrificed at day 24 by cervical dislocation under anesthesia.
Relative body weight at sacrifice was calculated as a percentage
relative to day 0. Statistical analysis was performed using one-way
ANOVA followed by Dunnett’s test for pairwise comparisons.
Four 4 mm thick mid-sagittal sections were obtained from both
hind limbs of each animal. Trabecular bone areas and tumor area
were measured from Masson-Goldner trichrome-stained sections
and osteoclasts in tumor-bone interface were calculated from
TRACP-stained sections. The number of osteoclasts was divided
by the length of tumor-bone interface. Statistical analysis was
performed using one-way ANOVA followed by Dunnett’s test for
pairwise comparisons.
Results
Anti-CD115 mAb Depletes TAMs and has Therapeutic
Effect in a Solid Tumor Model
Preliminary experiments were conducted to assess the mode of
action of mAb AFS98. Competition ELISA were performed, in
which soluble murine CD115-Fc was co-incubated with immobi-
lized murine or human CSF-1 in the presence of increasing
AFS98 concentrations (Figure S1). AFS98 blocked the binding of
CSF-1 from both species to mouse CD115, showing that its
inhibitory effect on the receptor function most probably relied on
competition with the ligand.
The effect of targeting CD115 with mAb AFS98 on tumor
growth was first studied in a cancer model using EL4 thymoma
cells implanted subcutaneously in the flanks of C57BL/6 mice.
EL4 cells are CD115-negative in vitro as determined by IC/FC
with mAb AFS98 (data not shown). Tumor growth was retarded in
mice treated for 3 weeks with the anti-CD115 mAb starting ten
days after implantation, compared to PBS-treated mice
(Figure 1A). Only the maximal tested dose of 50 mg/kg produced
a statistically significant reduction in tumor sizes (p = 0.0245 and
p= 0.0166 (n= 15) at days 23 and 27, respectively), while there
was no effect with 10 or 25 mg/kg. Consequently, survival was
significantly prolonged (p = 0.0368) only in mice treated with
50 mg/kg AFS98 (Figure 1B). F4/80 staining by IHC showed
that the macrophage population was strongly reduced in tumors
sampled during AFS98 treatment, both at days 20 (Figure 2A, B)
and 27 (data not shown). Expression of the M2-type macrophage
marker CD163 was also considerably decreased in EL4 tumors
from mice treated with 50 mg/kg AFS98 (Figure 2C, D). These
results suggest that the therapeutic effect of the anti-CD115 mAb
in this tumor model may be a consequence of M2-type TAM
depletion.
Because CSF-1 is normally cleared from the circulation by
CD115-mediated endocytosis [40] and since AFS98 prevents
CSF-1/CD115 binding, we titrated the levels of circulating CSF-1
after only one mAb injection. As soon as one day post-
administration, AFS98 at all doses tested dramatically increased
CSF-1 serum concentrations (Figure S2). While serum CSF-1
was hardly detectable by ELISA in buffer-treated mice, its
concentration reached 2000 pg/ml one day after AFS98 injection.
The importance and duration of CSF-1 accumulation in the
serum was correlated with the doses of AFS98 administered. At
25 or 50 mg/kg, AFS98 had an even more drastic effect on CSF-1
serum concentration, which was still increased 19 days after
injection of 50 mg/kg. This result may explain the high dose of
AFS98 (50 mg/kg) required to achieve a therapeutic effect, since
the mAb must compete with CSF-1 for CD115 binding.
Anti-mouse CD115 mAb Treatment Delays the
Appearance of Mammary Tumors in PyMT Mice
Transgenic MMTV-PyMT mice, expressing the polyoma
middle T oncogene under control of the mouse mammary tumor
virus promoter, spontaneously develop mammary tumors with
stages comparable to the human situation [16,39]. Based on the
four-stage classification described in PyMT mice bred on a C3H/
B6 background by Lin et al [39], we have characterized
histologically the progression of mammary tumors in PyMT mice
on the C57BL/6 genetic background (Figure 3). At 4 weeks of
age, a few mammary glands were hyperplasic with epithelial cells
proliferating within acini and forming focal or multifocal clusters
on terminal ducts. In addition to the hyperplasia, adenomas
(mammary intraepithelial neoplasia MIN) were observed at 6
weeks of age, characterized by solid sheets of proliferating
epithelial cells completely filling the acini but still confined by a
basement membrane. Foci of leukocytic infiltration were associ-
ated with increased vascularization. The initial stage of malignant
transition, termed early carcinoma (EC), was first detected starting
at 10 weeks of age. EC was characterized by a change in nuclear
morphology, the disappearance of basement membranes and high
density leukocyte infiltrates surrounding the acini. Mammary
tumors became palpable between 13 and 14 weeks of age and on
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week 16, all mice had palpable tumors. Advanced invasive (late)
carcinomas (LC) appeared around 18 weeks of age, characterized
by solid sheets of epithelial cells and the loss of acinar structures,
with the disappearance of basement membranes and the presence
of necrotic areas. LC were always associated with lung metastasis.
Figure 1. Therapeutic effects of anti-mouse CD115 mAb in the EL4 solid tumor model. Tumor-bearing mice were treated with 10, 25 or
50 mg/kg of mAb AFS98 or PBS, IP, starting from day 7 after tumor implantation. A. Tumor volumes are shown as means 6 SEM. * Mann-Whitney’s
test p,0.05 compared with the tumor volumes of PBS-treated mice (n = 15). B. Percentages of surviving mice in each group. * Log-rank test p,0.05
compared with the PBS-treated mouse group (n = 15).
doi:10.1371/journal.pone.0073310.g001
Figure 2. Depletion of M2-polarized TAMs by anti-mouse CD115 mAb in EL4 solid tumors. EL-4 tumors sampled at day 20 from mice
treated with either PBS (A, C, E) or 50 mg/kg mAb AFS98 (B, D, F) were analyzed by IF with anti-F4/80 mAb (A, B), anti-CD163 mAb (C, D) or irrelevant
isotype control (E, F). Blue : DNA; Red : F4/80+ macrophages (A, B) or CD163+ M2-type macrophages (C, D). Sections shown were obtained from one
tumor representative of 3 analyzed per group. F4/80 (G) and CD163 (H) staining were quantified in the tumors shown in A-D.
doi:10.1371/journal.pone.0073310.g002
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We aimed at studying the effect of anti-CD115 mAb treatment
on the development of these mammary tumors. On tumor sections
at the EC stage, all F4/80-positive infiltrating macrophages were
stained with an anti-CD115 antibody (Figure S3). In contrast,
PyMT tumor cells do not express CD115 [16] and therefore
cannot be directly targeted by AFS98 treatment. The mAb was
administered (50 mg/kg, IP 3 times per week) to PyMT mice from
week 10 to 13, at the time of MIN to EC transition (Figure 3).
Palpable mammary tumors appeared significantly later (15.8+/
20.9 weeks, n = 10) than in mice treated with isotype control
(13.8+/21.4 weeks, p = 0.0112, n= 10) or with PBS (14.4+/21.1
weeks, p = 0.020, n = 10) (Figure 4A). Tumor sizes were
significantly reduced with AFS98 at week 13 (p = 0.0149 vs PBS
and p= 0.0098 vs rat IgG) and at week 14, after termination of the
treatment (p = 0.0183 vs rat IgG- and p= 0.0212 vs PBS-treated
mice) (Figure 4B). AFS98 treatment significantly prolonged
survival when compared with rat IgG (p = 0.018) (Figure 4C). Of
note, treatment with rat IgG had a deleterious effect on survival
when compared to the PBS-treated group (p= 0.0283). The
therapeutic effect of the anti-CD115 mAb was lost two weeks after
cessation of the treatment. This may be explained by the dramatic
upregulation of circulating CSF-1, occurring in C57BL/6 (Figure
S2) and in PyMT mice (data not shown) following multiple mAb
administration.
As found in the EL4 SC tumor model, the macrophage marker
F4/80 was strongly decreased in primary mammary tumors from
PyMT mice treated with 50 mg/kg AFS98 sampled one week
after cessation of the treatment, compared to PBS-treated mice
(Figure 5A, B, G). The number of M2-polarized macrophages
identified by CD163 staining was also reduced in tumors from
anti-CD115-treated mice (Figure 5C, D, H). However, angio-
genesis was not detectably inhibited as found by CD31 staining of
these tumors, sampled one week after cessation of the treatment
(data not shown).
Late Anti-mouse CD115 mAb Treatment Prolongs the
Survival of PyMT Mice and Potentiates the Effect of
Chemotherapy
We then studied the effect of anti-CD115 mAb treatment
administered later during tumor progression. AFS98 was dosed
(50 mg/kg, IP 3 times per week, for 3 weeks) starting from week
16, when all tumors were palpable, mostly at the EC stage without
yet reaching the LC stage (Figure 3). One week after termination
of the treatment (week 20), the sizes of primary tumors were
significantly reduced in the AFS98-treated group compared to the
PBS- (p = 0.0101, n= 10) but not to the IgG-treated mice
(p = 0.1457, n= 10) (Figure 6A). Survival was significantly
prolonged by AFS98 compared to either PBS (p= 0.0031) or
IgG (p= 0.0474) (Figure 6B). As seen when treatment was
initiated earlier (Figure 5), depletion of CD163+ macrophages
was observed in tumors from mice treated with AFS98 (Figure
S4).
To study the effect of the anti-CD115 mAb in association with
chemotherapy, we combined the latter AFS98 treatment with
Paclitaxel (5 mg/kg, IP 1 time per week). Paclitaxel at this dose
did not show significant therapeutic effects, but a trend towards
reduction in tumor growth. In PyMT mice treated with Paclitaxel
combined with AFS98, the sizes of primary tumors were
significantly reduced compared with PBS (p = 0.0155, p = 0.0039
and p= 0.0009 at week 17, 18 and 19, respectively, n = 10) or rat
IgG (p= 0.0077, p= 0.0022 and p= 0.0005 at week 17, 18 and 19,
respectively, n = 10) (Figure 6C). Survival was significantly
prolonged when Paclitaxel was combined with AFS98, compared
to either PBS (p = 0.0014) or IgG (p = 0.00072) (Figure 6D),
showing that anti-CD115 mAb treatment could potentiate the
effect of chemotherapy.
Anti-mouse CD115 mAb Inhibits Osteoclasts and Bone
Destruction in a Breast Cancer Bone Metastasis Model
We investigated the effect of CD115 blockade on metastasis-
induced osteoclastic bone degradation. To this end, we made use
of a model in which human breast cancer cells are injected in the
left cardiac ventricles of athymic mice to induce osteolytic bone
metastasis [37,41]. MDA-MB231 cells are known to secrete
human CSF-1 [42], which can activate murine CD115 [7]. MDA-
MB231 cells are reported to also express human CD115 [42], but
mAb AFS98 is specific for murine CD115 [34]; therefore, in this
model, anti-CD115 mAb treatment will only target the murine
myeloid cell compartment. Treatment of mice with 50 mg/kg
mAb AFS98 potently inhibited the development of the osteolytic
lesions visualized by X-ray radiography (Figure 7A). AFS98
displayed an activity similar to zoledronic acid, a standart-of-care
Figure 3. Progression of mammary tumors in C57BL/6 PyMT mice. Percentile distribution of tumor stages characterized by histopathology.
Four to six mammary glands were removed from 2 to 6 PyMT mice at the indicated ages.
doi:10.1371/journal.pone.0073310.g003
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inhibitor of osteolysis which was used as positive control. Both
compounds diminished the area as well as the number of
osteoclastic lesions, compared with PBS or rat IgG controls.
AFS98 and zoledronic acid were equally potent at decreasing
osteoclast numbers, as shown by the osteoclast marker Tartrate-
resistant acid phosphatase 5b (TRACP 5b) which was diminished
in the serum of mice at days 17 (data not shown) and 24
(Figure 7B). As measured by histomorphometry, osteoclast
numbers at the tumor-bone interface were strongly decreased by
AFS98 or zoledronic acid. Both compounds increased total and
trabecular bone areas, with a stronger effect of zoledronic acid on
trabecular bone areas (Figure 7C). Cancer-associated weight loss
was inhibited similarly by zoledronic acid or AFS98. The MDA-
MB231 cell line used in this study stably expresses GFP [37].
Whole body tumor burden analyzed by fluorescence imaging was
not modified by either anti-CD115 mAb or zoledronic acid
treatment, compared with control animals (data not shown).
Altogether, these results show that the anti-CD115 mAb inhibits
metastasis-induced bone destruction by targeting osteoclasts.
Discussion
This study demonstrates for the first time that targeting CD115
on cancer host cells using a blocking mAb (i) depletes CD163+ M2-
type TAMs and inhibits tumor growth in either ectopic or
spontaneous cancer models; (ii) has therapeutic activity at early or
late cancer stages in a model recapitulating the progression of
human breast cancer, where it potentiates the effect of chemo-
therapy; and (iii) inhibits metastasis-induced bone degradation by
decreasing osteoclast numbers.
Attempts to target the CD115/CSF-1 pathway in order to
inhibit TAMs in mouse tumor models have been reported using
various strategies [5,43–46] and notably using mAbs [47–50].
McDonald et al. found in two transplanted syngenic tumor models
(AE5MG mesothelioma and LLC lung carcinoma) that an anti-
mouse CD115 IgG1 named M279) depleted F4/80
+/Gr12
monocytes and TAMs but did not affect tumor growth [49].
Kubota et al, with the same mAb as the one used in this study,
could inhibit the growth and metastasis of AX tumors and showed
that TAMs were depleted [47]. In our study, treatment of EL4
tumors with mAb AFS98 resulted in slower tumor growth and in
prolonged mouse survival. In agreement with the previous studies,
the anti-CD115 mAb depleted tumor-associated F4/80+ cells. Our
results show in addition that anti-CD115 mAb treatment inhibits
the infiltration of CD163+ F4/80+ TAMs, corresponding to
alternatively-activated or M2-type macrophages. This supports the
role of M2-polarized TAMs in promoting tumor growth in the
EL4 tumor model. We did not detect changes in tumor
vasculature whether mice were treated or not with AFS98, in
contrast to the results reported upon treatment of AX tumor-
bearing mice [47]. This was unexpected, given the known role of
macrophages in tumor angiogenesis [17]. The therapeutic effects
observed in the EL4 tumor model may be related to the inhibition
of other TAM functions, including immunomodulation.
Since a spontaneous tumor model would better reflect the
natural process of cancer progression, we studied the effects of
targeting CD115 with AFS98 in MMTV-PyMT mice. Lin et al.
[16,17] previously showed using this mouse model that the
CD115/CSF-1 axis was involved in the progression of mammary
cancer, regulated by macrophages. Our results show for the first
Figure 4. Appearance and progression of palpable mammary tumors are delayed in PyMT mice treated with AFS98. At 10 weeks of
age, MMTV-PyMT mice were treated with 50 mg/kg of mAb AFS98, control rat IgG or PBS, injected IP 3 times per week from week 10 to week 13. A.
The appearance of palpable tumors was delayed in AFS98-treated mice. The mean age (in weeks 6 SEM) of palpable tumor detection is shown for
each of the 3 mouse groups. * Mann-Whitney’s test p,0.05 compared with Rat IgG and PBS-treated mouse group (n = 10). B. Tumor volumes are
shown as means 6 SEM. * significant difference in tumor volume using Mann-Whitney’s test, p,0.05 between groups treated with Rat IgG and PBS
(n = 15). C. Percentages of surviving mice in each group. * Log-rank test p,0.05 compared with the indicated mouse group (n = 10).
doi:10.1371/journal.pone.0073310.g004
Anti-CD115 Immunotherapy in Mouse Cancer Models
PLOS ONE | www.plosone.org 6 September 2013 | Volume 8 | Issue 9 | e73310
time that treating PyMT mice with an anti-CD115 mAb around
the time of malignant transformation delays the appearance of
palpable primary tumors, suggesting that the CD115 axis is
already involved in the early stages of carcinogenesis. Like in the
EL4 cancer model, this therapeutic effect was correlated with the
depletion of CD163+ M2-type TAMs. The fact that blocking
CD115 gives a therapeutic benefit at this early timepoint during
carcinogenesis suggests that preventing M2-type macrophage
recruitment and/or of differentiation delays malignant transfor-
mation. Lin et al. [16] found that CSF-1 did not regulate the
initial growth of primary PyMT tumors, but only their progression
through its effect of TAMs and angiogenesis. Further studies are
needed to determine whether the alternative CD115 ligand, IL-34,
rather than CSF-1, might be involved in this early oncogenic
process. Unexpectedly, we were unable to detect any inhibitory
effect of the anti-CD115 mAb on tumor angiogenesis, despite the
fact that macrophages - required for the ‘‘angiogenic switch’’ and
malignant transformation [17] - were clearly diminished in the
tumors sampled on week 14, one week after cessation of the
treatment. Macrophage-induced angiogenesis might have oc-
curred prior to initiation of the treatment, before progression
from the neoplastic to the malignant stage around week 10.
Indeed, Lin et al. found that macrophage infiltration preceeded
PyMT tumor progression from the neoplastic to the early
carcinoma stage [17]. However, we cannot rule out tumor
angiogenesis was impacted only during the treatment period and
was restored one week later, at the time of observation.
When administered to PyMT mice already bearing malignant
tumors, the anti-CD115 mAb also inhibited tumor growth and
prolonged mouse survival. Taken together with the previous
results, this suggests that the CD115 pathway is involved both
during early mammary tumorigenesis and at later stages of cancer
progression. It had already been shown that progression through
malignant and metastatic stages of PyMT tumors depended on
CSF-1 and TAMs [5,16]. This is further supported by the
therapeutic effect of AFS98 observed in mice already bearing
malignant tumors.
After only one administration of AFS98, serum CSF-1
concentrations were dramatically increased. This was expected
because AFS98 blocks CSF-1 binding to CD115 and the cytokine
is normally cleared from the circulation through receptor-
mediated endocytosis. This strong effect on plasmatic CSF-1
levels has already been reported for another anti-CD115 mAb,
M279 [49]. This phenomenon may represent a hurdle for anti-
CD115 immunotherapy, since overwhelming cytokine activity
after cessation of the treatment or in organs which are inaccessible
to mAbs may result in counter-productive and even toxic effects.
For administration to cancer patients, a mAb which could inhibit
CD115 function without preventing CSF-1 capture and degrada-
tion may be preferable to a ligand-competitive mAb.
In an implanted PyMT tumor model, De Nardo et al. have
recently shown that an anti-CSF-1 mAb could decrease TAM
infiltration, but lacked therapeutic effect unless combined with the
chemotherapeutic agent Paclitaxel [50]. In the PyMT spontaneous
tumor model used in our study, the anti-CD115 mAb by itself
Figure 5. Anti-CD115 mAb treatment depletes TAMs and M2-type macrophages in PyMT mouse tumors. F4/80 (A, B) or CD163 (C, D)
expression in mammary tumors sampled at week 14 from mice treated with either PBS (A, C) or mAb AFS98 (B, D). Staining with irrelevant isotype
control is shown in E, F. Sections shown were obtained from one mouse representative of 3 analyzed per group. Blue: DNA; Red: F4/80+ (A, B) or
CD163+ (C, D) macrophages. F4/80 (G) and CD163 (H) staining were quantified in the tumors from mice treated with either PBS, control rat IgG or
mAb AFS98.
doi:10.1371/journal.pone.0073310.g005
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could efficiently reduce tumor growth, suggesting that targeting
the receptor might have a superior therapeutic effect than blocking
CSF-1. The alternative ligand IL-34 could be responsible for
activating the CD115 pathway within mammary tumors. De
Nardo et al. found that cytotoxic therapy induced both CSF-1 and
IL-34 production by mammary carcinoma cells, increasing TAM
infiltration. In mice bearing xenografted MCF-7 breast tumors, a
PEG-conjugated anti-CSF-1 Fab was reported to have therapeutic
effect, reducing macrophage recruitment to the tumor and
reversing tumor resistance to combined chemotherapy [48]. In
line with these previous studies, our results in the PyMT mouse
model show that anti-CD115 mAb potentiates the effect of
Paclitaxel for inhibiting tumor growth and prolonging survival,
providing another piece of evidence that targeting TAMs will
ameliorate the efficacy of chemotherapeutic treatments.
The inhibition of metastasis-induced osteolysis by anti-CD115
immunotherapy is demonstrated for the first time in this study.
The breast cancer metastasis model addresses the effect of the
CD115 mAb on bone-resorbing osteoclasts induced by tumor cells
secreting CSF-1. Since mAb AFS98 does not bind human CD115,
it could not directly affect the growth of MDA-MB231 tumor cells.
Small molecule TK inhibitors targeting CD115 have been shown
efficacious in inhibiting cancer-induced osteolysis [46,51–53],
although it remained unclear whether this was due to an effect on
tumor cells, on mouse osteoclasts, or even on another TKR - since
small molecule TK inhibitors generally lack selectivity. Our results
show for the first time that a mAb targeting host CD115+ myeloid
cells can inhibit bone degradation induced by breast cancer
metastases. AFS98 was as potent as a biphosphonate in decreasing
osteoclast numbers and osteolytic lesions. Importantly, the mAb
also prevented cancer-induced weight loss, suggesting that anti-
CD115 immunotherapy could improve the quality of life for
cancer patients.
Together, these results show that targeting CD115+ cells in the
tumor microenvironment with a function-blocking mAb can have
therapeutic effects through the dual inhibition of TAMs and
osteoclasts. They support the clinical development of an anti-
human CD115 mAb, which might be more specific and less toxic
than a TKI, in cancer indications characterized by TAM
infiltration and osteolytic bone metastases.
Figure 6. Therapeutic effects of anti-mouse CD115 mAb alone or combined with Paclitaxel in the PyMTmouse model. At 16 weeks of
age, transgenic PyMT mice were administered 50 mg/kg of mAb AFS98 or isotype control or PBS, IP, 3 times per week for 4 weeks, alone (A, B) or
combined (C, D) with Paclitaxel at 5 mg/kg, IP, once a week for 3 weeks. A. Tumor volumes are represented as means 6 SEM. * Mann-Whitney’s test
p,0.05 for AFS98- compared to PBS-treated mice. At week 20, * p,0.05 for AFS98- and Rat IgG- vs PBS-treated mice. B. The percentage of surviving
mice was significantly increased in the AFS98-treated group. * Log-rank test p,0.05 between AFS98- and Rat IgG-treated groups and ** p,0.005
between AFS98- and PBS-treated mice (n = 10). C. Tumor volumes are represented as means 6 SEM. * Mann-Whitney’s test p,0.05 for the
combination Paclitaxel+AFS98 compared with Paclitaxel+PBS, and p,0.01 compared with Paclitaxel+Rat IgG. **p,0.01 and ***p,0.001 for
Paclitaxel+AFS98 compared with Paclitaxel+Rat IgG or PBS (n = 10). D. The percentage of surviving mice was significantly increased by AFS98
combined with Paclitaxel. ** Log-rank test p,0.01 for mice treated with Paclitaxel+AFS98 compared to Paclitaxel+Rat IgG or PBS.
doi:10.1371/journal.pone.0073310.g006
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Supporting Information
Figure S1 Competition of AFS98 with mCSF-1 or hCSF-1
for mouse CD115 binding. Microplate wells were coated with
0.1 mg of either mouse or human CSF-1 and the binding of mouse
M-CSFR-Fc added at 0.1 mg/mL was assessed in the presence of 4
concentrations of AFS98 or control mAb (Rat IgG2a). Binding of
mouse CD115-Fc was detected using a HRP conjugated antibody
that recognized the Fc part of the recombinant antigen. MAb
AFS98 dose-dependently blocks mCSF-1 and hCSF-1 binding to
mCD115.
(DOCX)
Figure 7. Therapeutic and osteoclast-inhibitory effects of anti-mouse CD115 mAb in a breast cancer metastasis-induced osteolysis
model. Athymic nude mice implanted with MDA-MB231 tumor cells were treated with mAb AFS98, control rat IgG (both IP at 50 mg/kg, IP 3 times a
week), zoledronic acid (0.1 mg/kg) or PBS (both SC, on days 0 and 14). 7.A. Bone-protective effect of anti-CD115 mAb. Osteolytic lesions were
measured at the end of the experiment. Left: Total osteolytic lesion areas (mm2, mean+SD) are shown as the sums of the areas of the bone lesions in
right and left tibia and femur. Right: Number of osteolytic lesions (mean+SD). The results are shown as the counts of individual bone lesions in right
and left tibia and femur. 7.B. Osteoclast-inhibitory effect of anti-CD115 mAb. Left: The osteoclast marker TRACP 5b was titrated in serum sampled at
day 24. Results are expressed as relative change (%) in serum TRACP 5b from day 0 to day 24 (mean+SD). Right: Sections from hind limbs of each
animal were stained for TRACP 5b and osteoclast numbered at the tumor-bone interface (mean+SD). Osteoclast numbers were divided by the length
of this interface. 7.C. Effects of anti-CD115 mAb on trabecular bone and inhibition of cancer-induced weight loss. Left: Trabecular bone area (mm2,
mean+SD) of each animal was determined by histomorphometry. The results shown are the sums of trabecular bone areas in right and left tibia and
femur. Right: Relative body weight at sacrifice (%, relative to day 0, mean+SD). *p,0.05; **p,0.01 and ***p,0.001 compared with control, using the
statistical tests indicated in Materials and Methods.
doi:10.1371/journal.pone.0073310.g007
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Figure S2 Treatment with mAb AFS98 strongly increas-
es serum CSF-1. C57BL/6 mice were injected IP with mAb
AFS98 at 10, 25 or 50 mg/kg or PBS. Serum was collected at the
indicated days after injection and titrated for mCSF-1 by ELISA
(Duoset, R&D Systems).
(DOCX)
Figure S3 Double immunofluorescence staining for F4/
80 and CD115 on FFPE sections from MMTV-PyMT
mouse mammary tumors. To better characterize the CD115-
positive cells in mammary tumors from MMTV-PyMT mice,
Formalin-Fixed Paraffin-Embedded sections from tumors at the
EC stage were double-stained with antibodies to F4/80 and
CD115 (rabbit anti-CD115, C20, Santa Cruz). Not all CD115-
positive cells co-expressed F4/80, but all F4/80-positive macro-
phages were also stained with the anti-CD115 antibody, reflecting
a tumor-associated macrophage phenotype.
(DOCX)
Figure S4 TAM and M2-type macrophage inhibitory
effects of anti-CD115 mAb administered to PyMT mice
starting at 16 weeks of age. F4/80 (A, B) or CD163 (C, D)
expression in mammary tumors sampled at week 20 from mice
treated with either PBS (A, C) or mAb AFS98 (B, D). Staining with
irrelevant isotype control is shown in E, F. Sections shown were
obtained from one mouse representative of 3 analyzed per group.
Blue: DNA; Red: F4/80+ (A, B) or CD163+ (C, D) macrophages.
Sections shown were obtained from one tumor representative of 3
analyzed per group. F4/80 (G) and CD163 (H) staining were
quantified in the tumors shown in A-D.
(DOCX)
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